Table 2.
Follow-up of patients treated with BM-MNCs.
| All (N = 22) | Spanish trial (N = 10) | Brazilian trial (N = 12) | p | |
|---|---|---|---|---|
| Death | — | — | — | — |
| Stroke | — | — | — | — |
| MI | — | — | — | — |
| Infection | 4 (18.2%) | 4 (40%) | 0 (0%) | 0.03∗ |
| SICH | — | — | — | — |
| Allergic reaction | — | — | — | — |
| Tumors | — | — | — | — |
| Seizure | 7 (31.8%) | 2 (20%) | 5 (41.7%) | 0.38 |
| NIHSS 30 | 9.0 [6.0–12.0] | 9.0 [7.0–13.0] | 10.0 [5.2–12.0] | 0.80 |
| NIHSS 90 | 6.5 [4.7–11.2] | 6.5 [5.7–11.7] | 7.5 [4.0–11.7] | 0.77 |
| NIHSS 180 | 6.0 [4.0–10.2] | 6.0 [3.7–11.2] | 8.0 [4.2–10.7] | 0.67 |
| mRS ≤ 2 30 | 3 (13.6%) | 1 (10%) | 2 (16.7%) | 0.99 |
| mRS ≤ 2 90 | 5 (22.7%) | 1 (10%) | 4 (33.3%) | 0.32 |
| mRS ≤ 2 180 | 5 (22.7%) | 2 (20%) | 3 (25%) | 0.99 |
∗ p < 0.05.